Assess Quality of Life in Hearing Aid Patients Suffering From oTOTOXicity Due to Platinum-based Chemotherapy (PROTOTOX)

Assess Quality of Life in Hearing Aid Patients Suffering From oTOTOXicity Due to Platinum-based Chemotherapy

Assess Quality of Life in Hearing Aid Patients Suffering From oTOTOXicity Due to Platinum-based Chemotherapy

There are many undesirable effects associated with platinum-based cancer treatments (renal failure, anaemia, etc.). Their administration also leads to neurosensory problems such as ototoxicity, tinnitus and reduced hearing acuity. According to a French survey (2018), 39.7% of people suffer from hearing problems due to cancer treatments, five years after a cancer diagnosis. Improving side effects such as hypoacusis and tinnitus can significantly improve patients' quality of life and adherence to treatment. Many clinical trials proposed a medicinal solution to patients receiving platinum-based cancer treatments have but none has led to a consensus on management. The aim of the study is to offer patients receiving platinum-based chemotherapy and suffering from hearing problems a hearing aid to improve their quality of life.

At baseline, medical staff carries out a clinical and audiometric and/or tintometric examination patient completes the SF36 survey (36 Item Short-Form Health Survey) According to test results, the medical staff suggests that the patient be referred to a hearing aid specialist for fitting with a hearing aid. Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology. At one and three months after fitting, medical staff carries out a clinical examination patient receiving platinum-based chemotherapy completes the 36 Item Short-Form Health Survey (SF36). At six months after fitting; medical staff carries out a clinical and audiometric and/or tintometric examination patient receiving platinum-based chemotherapy completes the 36 Item Short-Form Health Survey (SF36).

The quality of life of patients with hearing aids suffering from ototoxicity due to platinum-based chemotherapy will be assessed using the 36 Item Short-Form Health Survey (SF36). [score 0 to 100 : score 0 representing the lowest possible scores and score 100 representing the highest possible scores. A higher score means better health.

Hearing and the onset of tinnitus in hearing-aided patients suffering from chemotherapy-induced ototoxicity will be assessed by Hertz/Decibel measurement using an audiometer

Hearing aid compliance will be assessed according to the proportion of patients completing 6-month follow-up with a hearing aid among all included patients.

Inclusion Criteria: Age ≥ 18 Patients undergoing platinum-based chemotherapy with hearing loss or worsening of an existing hearing loss concordant with the start of platinum-based chemotherapy. Patient having understood, signed and dated the consent form Patient affiliated to the social security system Exclusion Criteria: Patients with contraindications to wearing hearing aids Patients already wearing hearing aids Patient already included in an other clinical study with an experimental molecule Patients who have not started platinum-based chemotherapy Patient presenting only tinnitus without hearing loss Persons deprived of liberty or under guardianship (including curators) Women who are pregnant, may become pregnant or are breast-feeding Impossibility to undergo medical follow-up of the trial for geographical, social or psychological reasons